U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H26O2
Molecular Weight 298.4192
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORETHINDRONE

SMILES

[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]23[H]

InChI

InChIKey=VIKNJXKGJWUCNN-XGXHKTLJSA-N
InChI=1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H26O2
Molecular Weight 298.4192
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8520623 https://www.medicines.org.uk/emcmobile/PIL.23891.latest.pdf http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018405s023lbl.pdf

Norethisterone (INN, BAN), also known as Norethindrone (USAN) (brand names Micronor, AYGESTIN, numerous others) is a synthetic progestational hormone (progestin) with actions similar to those of progesterone but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with oncomitant estrogen therapy in postmenopausal women for endometrial protection. Progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH surge. Allergic reaction could be: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rat. Human data not available Norethindrone affects the levels of opioid petides in the rat brain, but it is not clear whether this action is mediated by direct activity within CNS

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.8 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MICRONOR

Approved Use

Indications Progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. Efficacy If used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.5%. However, the typical failure rate is estimated to be closer to 5%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. Adapted from Hatcher et al, 1998, Ref. #1 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral® (1 dose is 2 white pills), Alesse® (1 dose is 5 pink pills), Nordette® or Levlen® (1 dose is 2 light-orange pills), Lo/Ovral® (1 dose is 4 white pills), Triphasil ® or Tri-Levlen® (1 dose is 4 yellow pills) Lactational Amenorrhea Method: LAM is highly effective, temporary method of contraceptionHowever, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussel J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year Method (1) Typical UseAmong typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason (2) Perfect UseAmong couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason (3) (4) ChanceThe percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether 85 85 SpermicidesFoams, creams, gels, vaginal suppositories, and vaginal film 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases 2 Post-Ovulation 1 CapWith spermicidal cream or jelly Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Withdrawal 19 4 CondomWithout spermicides Female (Reality®) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera® 0.3 0.3 70 Norplant® and Norplant-2® 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Norethindrone tablets have not been studied for and are not indicated for use in emergency contraception.

Launch Date

9.4780801E10
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

3.88108812E11
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

3.88108812E11
Primary
AYGESTIN

Approved Use

AYGESTIN® is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN® is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

Launch Date

3.88108812E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
26.19 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
166.9 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.51 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3%
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NORETHINDRONE plasma
Homo sapiens
population: HEALTHY
age: UNKNOWN
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 10.2-41.9 years
Health Status: unhealthy
Condition: Endometriosis
Age Group: 10.2-41.9 years
Sex: F
Sources:
Other AEs: Weight gain...
Other AEs:
Weight gain
Sources:
20 uCi single, intravenous
Dose: 20 uCi
Route: intravenous
Route: single
Dose: 20 uCi
Sources:
healthy, 25-35 years
n = 6
Health Status: healthy
Age Group: 25-35 years
Sex: F
Population Size: 6
Sources:
AEs

AEs

AESignificanceDosePopulation
Weight gain
15 mg 1 times / day multiple, oral
Studied dose
Dose: 15 mg, 1 times / day
Route: oral
Route: multiple
Dose: 15 mg, 1 times / day
Sources:
unhealthy, 10.2-41.9 years
Health Status: unhealthy
Condition: Endometriosis
Age Group: 10.2-41.9 years
Sex: F
Sources:
Overview

Overview

Drug as perpetrator​Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Induction of estrogen receptor-alpha and -beta activities by synthetic progestins.
2000 Apr
[A clinical assessment of a 3 month replacement therapy effectiveness with low norethisterone acetate (Activelle) in postmenopausal women].
2001
[Hormone replacement therapy in women with arterial hypertension in peri- and postmenopause: hemodynamic effects].
2001
Biphasic versus triphasic oral contraceptives for contraception.
2001
Biphasic versus monophasic oral contraceptives for contraception.
2001
Counting the costs: comparing depot medroxyprogesterone acetate and norethisterone oenanthate utilisation patterns in South Africa.
2001
Effects of 17 beta-estradiol and trimegestone alone, and in combination, on the bone and uterus of ovariectomized rats.
2001 Aug
Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy.
2001 Aug
Evaluation of interaction between fluconazole and an oral contraceptive in healthy women.
2001 Aug
Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals.
2001 Aug
Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women.
2001 Aug
Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study.
2001 Aug
Heparan sulfate mimetics modulate calpain activity during rat Soleus muscle regeneration.
2001 Aug
Omental pregnancy in a woman taking the progestogen-only pill.
2001 Dec
The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris.
2001 Dec
Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor.
2001 Dec 4
Fine structure of prolactin cell of female albino rat as affected by some antifertility drugs--a comparative electron microscopic study.
2001 Feb
Effect of trimegestone alone or in combination with estradiol on bone mass and bone turnover in an adult rat model of osteopenia.
2001 Feb
The insulin-like growth factor-I system and hormone replacement therapy.
2001 Feb
Effects of oral combined hormone replacement therapy on platelet aggregation in postmenopausal women.
2001 Feb
Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids.
2001 Feb
Solution structure and dynamics of an open beta-sheet, glycolytic enzyme, monomeric 23.7 kDa phosphoglycerate mutase from Schizosaccharomyces pombe.
2001 Feb 16
[Add back therapy for patients with endometriosis].
2001 Jan
Temporal changes in cardiac function and cerebral blood flow during sequential postmenopausal hormone replacement.
2001 Jan
Charcoal treatment and risk of escape ovulation in oral contraceptive users.
2001 Jan
Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone.
2001 Jul
Ovarian function during and after treatment with the new progestagen Org 30659.
2001 Jul
Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro.
2001 Jul 25
Continuous combined hormone replacement therapy with oral 17beta-estradiol and norethisterone acetate improves homocysteine metabolism in postmenopausal women.
2001 Jul-Aug
Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
2001 Jun
Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy.
2001 Jun
Effects of a monthly injectable steroidal contraceptive, Mesigyna, on menstrual pattern, lipoproteins, and coagulation parameters.
2001 Mar
The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
2001 Mar
Determination of steroid sex hormones and related synthetic compounds considered as endocrine disrupters in water by fully automated on-line solid-phase extraction-liquid chromatography-diode array detection.
2001 Mar 16
Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.
2001 May
Effects of oral and transdermal hormone replacement therapy on internal carotid artery pulsatility indices in postmenopausal women. A prospective, randomized, comparative study.
2001 Nov
Monitoring of solid-phase organic synthesis on macroscopic supports by high-resolution magic angle spinning NMR.
2001 Nov-Dec
Impact of oral contraceptive use on APC-resistance: a prospective, randomized clinical trial with three low-dose preparations.
2001 Oct
Estimation of hormone replacement therapy influence on serum galanin level in postmenopausal women.
2001 Sep
Validity of radioimmunological methods for determining free testosterone in serum.
2001 Sep
Mammographic density changes during different postmenopausal hormone replacement therapies.
2001 Sep
Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding.
2001 Sep
Progesterone and norethisterone have different effects on tachykinin-like immunoreactivity in rat cortex and striatum.
2001 Sep 15
Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens.
2001 Sep-Oct
Patents

Sample Use Guides

Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology: 2.5 to 10 mg may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Endometriosis: Initial daily dosage of 5 mg for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Growth of MCF-7 cells was stimulated by norethindrone (10(-8)-10(-5) M), with maximal growth stimulation at 10(-7) M norethindrone after 7 days of treatment
10 - 10000 nM norethindrone stimulates growth of MCF-7 cells
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:41:34 UTC 2023
Edited
by admin
on Wed Jul 05 22:41:34 UTC 2023
Record UNII
T18F433X4S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORETHINDRONE
HSDB   MI   ORANGE BOOK   USP   USP-RS   VANDF  
Common Name English
FEMCON FE COMPONENT NORETHINDRONE
Common Name English
NORETHINDRONE [USP IMPURITY]
Common Name English
NORETHISTERONUM [WHO-IP LATIN]
Common Name English
UTOVLAN
Common Name English
NORQUEST FE COMPONENT NORETHINDRONE
Common Name English
Norethisterone [WHO-DD]
Common Name English
NOR-QD
Brand Name English
NORETHINDRONE COMPONENT OF FEMCON FE
Common Name English
VYFEMLA COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE [MI]
Common Name English
NORETHISTERONE [MART.]
Common Name English
NORETHISTERONE ACETATE IMPURITY A [EP IMPURITY]
Common Name English
NORETHISTERONE [EP IMPURITY]
Common Name English
NORETHISTERONE
EP   INN   MART.   WHO-DD   WHO-IP  
INN  
Official Name English
SC-4640
Code English
CAMILA
Brand Name English
17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one
Common Name English
NORETHISTERON
Common Name English
NSC-9564
Code English
NORETHINDRONE [HSDB]
Common Name English
19-NORPREGN-4-EN-20-YN-3-ONE, 17-HYDROXY-, (17.ALPHA.)-
Common Name English
LO MINASTRIN FE COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE COMPONENT OF NORQUEST FE
Common Name English
MICRONOR
Brand Name English
TAYTULLA COMPONENT NORETHINDRONE
Brand Name English
TRIELLA
Common Name English
BREVICON COMPONENT NORETHINDRONE
Brand Name English
NORETHINDRONE [VANDF]
Common Name English
ARANELLE COMPONENT NORETHINDRONE
Common Name English
NORLUTIN
Brand Name English
NORETHINDRONE COMPONENT OF ARANELLE
Common Name English
ANOVULE
Common Name English
NORETHINDRONE [ORANGE BOOK]
Common Name English
norethisterone [INN]
Common Name English
NORETHINDRONE [USP MONOGRAPH]
Common Name English
NORETHINDRONE [USP-RS]
Common Name English
NORINYL COMPONENT NORETHINDRONE
Brand Name English
MINASTRIN 24 FE COMPONENT NORETHINDRONE
Brand Name English
GESTEST
Common Name English
NORETHISTERONE [JAN]
Common Name English
NORETHISTERONE [WHO-IP]
Common Name English
LEVONORGESTREL IMPURITY U [EP IMPURITY]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175602
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 18.3.1 (ETH/NOR)
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
NCI_THESAURUS C776
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
LIVERTOX 696
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03AA05
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03AC01
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
NDF-RT N0000011301
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-ATC G03AC01
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03FA01
Created by admin on Wed Jul 05 22:41:35 UTC 2023 , Edited by admin on Wed Jul 05 22:41:35 UTC 2023
WHO-ATC G03FA01
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03AB04
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-ATC G03FB05
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03DC02
Created by admin on Wed Jul 05 22:41:35 UTC 2023 , Edited by admin on Wed Jul 05 22:41:35 UTC 2023
WHO-ATC G03DC02
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-VATC QG03FB05
Created by admin on Wed Jul 05 22:41:35 UTC 2023 , Edited by admin on Wed Jul 05 22:41:35 UTC 2023
WHO-ATC G03AA05
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
WHO-ATC G03AB04
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
Code System Code Type Description
NSC
9564
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
EVMPD
SUB09362MIG
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
IUPHAR
2880
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
NORETHINDRONE
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY Description: A white or creamy white, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 150 parts of ethanol (~750 g/l) TS and in 80 parts of acetone R. Category: Progestational steroid. Storage: Norethisterone should be kept in a well-closed container, protected from light.Definition: Norethisterone contains not less than 97.0% and not more than 103.0% of C20H26O2, calculated with reference to thedried substance.
PUBCHEM
6230
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
DAILYMED
T18F433X4S
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
DRUG CENTRAL
1962
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
RS_ITEM_NUM
1469005
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
HSDB
3370
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
EVMPD
SUB87911
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
FDA UNII
T18F433X4S
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
MESH
D009640
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
RXCUI
7514
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY RxNorm
SMS_ID
100000092090
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
NCI_THESAURUS
C62059
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
ChEMBL
CHEMBL1162
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
MERCK INDEX
M8056
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
200-681-6
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
INN
687
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023380
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
DRUG BANK
DB00717
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
LACTMED
Norethindrone
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
CAS
68-22-4
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
WIKIPEDIA
NORETHISTERONE
Created by admin on Wed Jul 05 22:41:35 UTC 2023 , Edited by admin on Wed Jul 05 22:41:35 UTC 2023
PRIMARY
CHEBI
7627
Created by admin on Wed Jul 05 22:41:34 UTC 2023 , Edited by admin on Wed Jul 05 22:41:34 UTC 2023
PRIMARY
Related Record Type Details
METABOLITE LESS ACTIVE -> PARENT
Relative Binding Affinity (RBA) to Human Progesterone receptor (cytosol of human breast MCF-7 cells); Unit: % (relative to Org-2058 (=100%)); Norethindrone was 21.5%
IN-VITRO
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 3hr after 25mg single oral administration
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL (expressed as a mixture of the 3- (predominant) and 17-sulfate); 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE LESS ACTIVE -> PARENT
Unit: ng/ml; 25mg single oral administration (one female); blood was obtained 3hr after the oral ingestion
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
unit: ng/mL; 25mg single oral administration; blood sampled after 3hr
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
unit: mcg/24h; 1mg q.d. oral administration (w/50mcg estranol); blood sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 25mg single oral administration (one woman); blood was obtained 3hr after ingestion
IN-VIVO
PLASMA
METABOLITE LESS ACTIVE -> PARENT
Trace amount; Unit: mcg in a urine pool (2.5% aliquot from each of 4days of urine); 25mg q.d. oral administration (one woman)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 2mg (w/0.1mg mestranol) q.d. oral administration; blood was taken 3hr after the tenth pill ingestion on day 14 of the cycle (one woman)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mgg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
<2 to 12; Unit: ng/mL; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: mcg/24hr; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
<2; Unit: mcg/24hr; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: mcg in pooled urine (2.5% aliquot from each of the 4 days urine); 25mg q.d. oral administration for 4 days (one woman)
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration sampled on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
PARENT -> METABOLITE
Metabolite to parent drug ratio in non-uraemic human plasma. Norethynodrel is metabolized in man to the antifertility agent norethisterone(norethindrone).
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
METABOLITE INACTIVE -> PARENT
Unit: ng/ml; 2mg (w/0.1mg mestranol) q.d. oral administration (one woman); blood was taken 3hr after ingestion of the tenth pill on day 14 of the cycle
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: mcg in a urine pool (2.5% aliquot from each of 4 days of urine); 25mg q.d. oral administration for 4 days
IN-VIVO
URINE
METABOLITE LESS ACTIVE -> PARENT
Unit: ng/mL; 2mg (w/0.1mg mestranol) q.d. oral administration; blood was obtained 3hr after the tenth pill administration on day 14 of the cycle
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
Unit: ng/mL; 1mg (w/50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
PLASMA
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
IN-VIVO
URINE
METABOLITE INACTIVE -> PARENT
<2; Unit: mcg/24hr; 1mg (50mcg mestranol) q.d. oral administration; analyzed on the 7th, 14th, and 21st days (two females)
IN-VIVO
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC